Global Infectious Vaccines Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Infectious Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Infectious Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Infectious Vaccines market include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Infectious Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Infectious Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Infectious Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Infectious Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Infectious Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Infectious Vaccines sales, projected growth trends, production technology, application and end-user industry.
Infectious Vaccines Segment by Company
Sanofi Pasteur (France)
Johnson and Johnson (U.S.)
Novartis AG (Switzerland)
Merck and Company (U.S.)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc. (U.K.)
MedImmune LLC (U.S.)
Emergent Bio Solutions Inc. (U.S.)
CSL Limited (Australia)
Bavarian Nordic (Denmark)
Infectious Vaccines Segment by Type
Preventive Vaccine
Therapeutic Vaccine
Infectious Vaccines Segment by Application
Adults
Pediatrics
Infectious Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Infectious Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Infectious Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Infectious Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Infectious Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Infectious Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infectious Vaccines industry.
Chapter 3: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Infectious Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Infectious Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Infectious Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Infectious Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Infectious Vaccines market include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Infectious Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Infectious Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Infectious Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Infectious Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Infectious Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Infectious Vaccines sales, projected growth trends, production technology, application and end-user industry.
Infectious Vaccines Segment by Company
Sanofi Pasteur (France)
Johnson and Johnson (U.S.)
Novartis AG (Switzerland)
Merck and Company (U.S.)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc. (U.K.)
MedImmune LLC (U.S.)
Emergent Bio Solutions Inc. (U.S.)
CSL Limited (Australia)
Bavarian Nordic (Denmark)
Infectious Vaccines Segment by Type
Preventive Vaccine
Therapeutic Vaccine
Infectious Vaccines Segment by Application
Adults
Pediatrics
Infectious Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Infectious Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Infectious Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Infectious Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Infectious Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Infectious Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infectious Vaccines industry.
Chapter 3: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Infectious Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Infectious Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
190 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Infectious Vaccines Sales Value (2020-2031)
- 1.2.2 Global Infectious Vaccines Sales Volume (2020-2031)
- 1.2.3 Global Infectious Vaccines Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Infectious Vaccines Market Dynamics
- 2.1 Infectious Vaccines Industry Trends
- 2.2 Infectious Vaccines Industry Drivers
- 2.3 Infectious Vaccines Industry Opportunities and Challenges
- 2.4 Infectious Vaccines Industry Restraints
- 3 Infectious Vaccines Market by Company
- 3.1 Global Infectious Vaccines Company Revenue Ranking in 2024
- 3.2 Global Infectious Vaccines Revenue by Company (2020-2025)
- 3.3 Global Infectious Vaccines Sales Volume by Company (2020-2025)
- 3.4 Global Infectious Vaccines Average Price by Company (2020-2025)
- 3.5 Global Infectious Vaccines Company Ranking (2023-2025)
- 3.6 Global Infectious Vaccines Company Manufacturing Base and Headquarters
- 3.7 Global Infectious Vaccines Company Product Type and Application
- 3.8 Global Infectious Vaccines Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Infectious Vaccines Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Infectious Vaccines Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Infectious Vaccines Market by Type
- 4.1 Infectious Vaccines Type Introduction
- 4.1.1 Preventive Vaccine
- 4.1.2 Therapeutic Vaccine
- 4.2 Global Infectious Vaccines Sales Volume by Type
- 4.2.1 Global Infectious Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Infectious Vaccines Sales Volume by Type (2020-2031)
- 4.2.3 Global Infectious Vaccines Sales Volume Share by Type (2020-2031)
- 4.3 Global Infectious Vaccines Sales Value by Type
- 4.3.1 Global Infectious Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Infectious Vaccines Sales Value by Type (2020-2031)
- 4.3.3 Global Infectious Vaccines Sales Value Share by Type (2020-2031)
- 5 Infectious Vaccines Market by Application
- 5.1 Infectious Vaccines Application Introduction
- 5.1.1 Adults
- 5.1.2 Pediatrics
- 5.2 Global Infectious Vaccines Sales Volume by Application
- 5.2.1 Global Infectious Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Infectious Vaccines Sales Volume by Application (2020-2031)
- 5.2.3 Global Infectious Vaccines Sales Volume Share by Application (2020-2031)
- 5.3 Global Infectious Vaccines Sales Value by Application
- 5.3.1 Global Infectious Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Infectious Vaccines Sales Value by Application (2020-2031)
- 5.3.3 Global Infectious Vaccines Sales Value Share by Application (2020-2031)
- 6 Infectious Vaccines Regional Sales and Value Analysis
- 6.1 Global Infectious Vaccines Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Infectious Vaccines Sales by Region (2020-2031)
- 6.2.1 Global Infectious Vaccines Sales by Region: 2020-2025
- 6.2.2 Global Infectious Vaccines Sales by Region (2026-2031)
- 6.3 Global Infectious Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Infectious Vaccines Sales Value by Region (2020-2031)
- 6.4.1 Global Infectious Vaccines Sales Value by Region: 2020-2025
- 6.4.2 Global Infectious Vaccines Sales Value by Region (2026-2031)
- 6.5 Global Infectious Vaccines Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Infectious Vaccines Sales Value (2020-2031)
- 6.6.2 North America Infectious Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Infectious Vaccines Sales Value (2020-2031)
- 6.7.2 Europe Infectious Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Infectious Vaccines Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Infectious Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Infectious Vaccines Sales Value (2020-2031)
- 6.9.2 South America Infectious Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Infectious Vaccines Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Infectious Vaccines Sales Value Share by Country, 2024 VS 2031
- 7 Infectious Vaccines Country-level Sales and Value Analysis
- 7.1 Global Infectious Vaccines Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Infectious Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Infectious Vaccines Sales by Country (2020-2031)
- 7.3.1 Global Infectious Vaccines Sales by Country (2020-2025)
- 7.3.2 Global Infectious Vaccines Sales by Country (2026-2031)
- 7.4 Global Infectious Vaccines Sales Value by Country (2020-2031)
- 7.4.1 Global Infectious Vaccines Sales Value by Country (2020-2025)
- 7.4.2 Global Infectious Vaccines Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.9.2 France Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.16.2 China Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.19.2 India Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Infectious Vaccines Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Infectious Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Infectious Vaccines Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Sanofi Pasteur (France)
- 8.1.1 Sanofi Pasteur (France) Comapny Information
- 8.1.2 Sanofi Pasteur (France) Business Overview
- 8.1.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
- 8.1.5 Sanofi Pasteur (France) Recent Developments
- 8.2 Johnson and Johnson (U.S.)
- 8.2.1 Johnson and Johnson (U.S.) Comapny Information
- 8.2.2 Johnson and Johnson (U.S.) Business Overview
- 8.2.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
- 8.2.5 Johnson and Johnson (U.S.) Recent Developments
- 8.3 Novartis AG (Switzerland)
- 8.3.1 Novartis AG (Switzerland) Comapny Information
- 8.3.2 Novartis AG (Switzerland) Business Overview
- 8.3.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
- 8.3.5 Novartis AG (Switzerland) Recent Developments
- 8.4 Merck and Company (U.S.)
- 8.4.1 Merck and Company (U.S.) Comapny Information
- 8.4.2 Merck and Company (U.S.) Business Overview
- 8.4.3 Merck and Company (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
- 8.4.5 Merck and Company (U.S.) Recent Developments
- 8.5 Pfizer Inc. (U.S.)
- 8.5.1 Pfizer Inc. (U.S.) Comapny Information
- 8.5.2 Pfizer Inc. (U.S.) Business Overview
- 8.5.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
- 8.5.5 Pfizer Inc. (U.S.) Recent Developments
- 8.6 GlaxoSmithKline plc. (U.K.)
- 8.6.1 GlaxoSmithKline plc. (U.K.) Comapny Information
- 8.6.2 GlaxoSmithKline plc. (U.K.) Business Overview
- 8.6.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.6.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
- 8.6.5 GlaxoSmithKline plc. (U.K.) Recent Developments
- 8.7 MedImmune LLC (U.S.)
- 8.7.1 MedImmune LLC (U.S.) Comapny Information
- 8.7.2 MedImmune LLC (U.S.) Business Overview
- 8.7.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.7.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
- 8.7.5 MedImmune LLC (U.S.) Recent Developments
- 8.8 Emergent Bio Solutions Inc. (U.S.)
- 8.8.1 Emergent Bio Solutions Inc. (U.S.) Comapny Information
- 8.8.2 Emergent Bio Solutions Inc. (U.S.) Business Overview
- 8.8.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
- 8.8.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments
- 8.9 CSL Limited (Australia)
- 8.9.1 CSL Limited (Australia) Comapny Information
- 8.9.2 CSL Limited (Australia) Business Overview
- 8.9.3 CSL Limited (Australia) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.9.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
- 8.9.5 CSL Limited (Australia) Recent Developments
- 8.10 Bavarian Nordic (Denmark)
- 8.10.1 Bavarian Nordic (Denmark) Comapny Information
- 8.10.2 Bavarian Nordic (Denmark) Business Overview
- 8.10.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
- 8.10.5 Bavarian Nordic (Denmark) Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Infectious Vaccines Value Chain Analysis
- 9.1.1 Infectious Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Infectious Vaccines Sales Mode & Process
- 9.2 Infectious Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Infectious Vaccines Distributors
- 9.2.3 Infectious Vaccines Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


